Sanofi Partnership On Oral IL-17 Could Be Turning Point For C4XD
May Validate Small Molecule Platform
Executive Summary
The UK drug discovery specialist has made slow progress until now, but the Sanofi deal could yield a challenger in the competitive psoriasis field.
You may also be interested in...
UK Vaccine Taskforce’s Clive Dix: IP Is A Distraction, We Need To Vaccinate The World As Fast As Possible
Clive Dix, who recently stepped down as chair of the UK Vaccine Taskforce, shares his views on its success with Scrip, why AstraZeneca has been unfairly criticized, how the UK should now share its doses with other countries, and the exciting future of vaccine technology.
UK Vaccine Taskforce’s Clive Dix: IP Is A Distraction, We Need To Vaccinate The World As Fast As Possible
Clive Dix, who recently stepped down as chair of the UK Vaccine Taskforce, shares with Pink Sheet his views on its success, why AstraZeneca has been unfairly criticized, how the UK should now share its doses with other countries, and the exciting future of vaccine technology.
Bristol Lays Groundwork For First Dermatology Launch, Ahead Of TYK2 Inhibitor
The company has not even filed the TYK2 inhibitor deucravacitinib for psoriasis, but Bristol will be a new player in a category dominated by entrenched rivals.